Clinical Trials Logo
  1. Home
  2. Pituitary Diseases
  3. NCT03665064
  4. Details
NCT03665064 Clinical Trial

Long Term Outcome Study in Patients With Pituitary Disorders

Pituitary Diseases Clinical Trial

Official title:
Long Term Outcome Study in Patients With Pituitary Disorders

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT03665064
Other study ID # Pro00048323
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2000
Est. completion date December 31, 2024

Study information
Verified date February 2024
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.

Description:

A chart audit of around 1500 patients seen in two specific clinics, the Medical Pituitary Clinic and the combined Endocrine/Neurosurgical Pituitary Clinic at the University of Alberta Hospital, will be performed to determine the effectiveness of various treatment strategies on the long term outcome of specific pituitary disorders. The investigator's will collect retrospective demographic (age, sex, ethnicity), clinical (mode of presentation, hormonal parameters) and therapeutic outcome (surgical, medical, expectant and / or radiation treatment; co-morbidities and complications) of patients seen in these two clinics between January 2000 and December 2020.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 1500
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients with confirmed pituitary disease Exclusion Criteria: - patients who do not have confirmed pituitary disease

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
University of Alberta

Outcome
Type Measure Description Time frame Safety issue
Primary Progression free survival after pituitary surgery Using clinical, biochemical and imaging studies of a cohort of surgically operated patients to identify prognostic factors of tumor recurrence up to 17 years post surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04897802 - Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) Phase 4
Completed NCT03137615 - The Cardiovascular Changes Associated With Septal Local Anaesthesia N/A
Completed NCT03305016 - A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency Phase 3
Completed NCT02084134 - Peri-Operative Steroid Management in Patients N/A
Completed NCT00234533 - Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Phase 3
Completed NCT04902235 - Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) Phase 4
Recruiting NCT04951557 - Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas
Active, not recruiting NCT00473369 - Prognosis of Atypical Pituitary Adenomas N/A
Recruiting NCT06435195 - Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases
Completed NCT02782208 - Lipolytic Effects of GH in Hypopituitary Patients in Vivo N/A
Recruiting NCT04326374 - Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency Phase 3
Completed NCT03344458 - A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial Phase 3
Completed NCT02781727 - A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Phase 3